Smith+Nephew Lowers Revenue Forecast Despite Strong H1 Profit; Buyback Advances
SNN is trading near its 52-week low of $28.555 (7.5% above the low).
Summary
Smith+Nephew posted an 8.1% rise in H1 2026 trading profit to $566M, but softer Q2 sales forced a reduction in full-year revenue growth guidance to ~4% from ~6%. Profit and cash flow guidance were held steady, the dividend was increased, and the $500M buyback is progressing.
Key Events · Earnings and Guidance · SNN
-
Revenue Miss, Guidance Cut
Underlying revenue grew only 1.6% in Q2, missing expectations, as softness in US Orthopaedics and Advanced Wound Bioactives weighed on performance. Consequently, full-year revenue growth guidance was trimmed to ~4% from ~6%.
-
Profit Beat on Efficiency Gains
H1 trading profit climbed 8.1% to $566M, with the margin expanding 60bps to 18.3%, as $130M in efficiency savings more than compensated for the revenue shortfall. Full-year trading profit guidance of ~$1.3B was reaffirmed.
-
Buyback Progress & Dividend Hike
As of 3 August 2026, $216M of the $500M buyback program has been settled. Reflecting confidence in cash generation, the interim dividend was raised 4.0% to 15.6¢ per share.
-
Orthopaedics Challenges Persist
US Knee Implants declined 7.2% in Q2, hampered by portfolio gaps and the market's shift to cementless solutions; US Hip Implants fell 1.5% due to set deployment delays. Management expects new product launches to drive improvement in the second half.
Analysis · SNN · Industrial Applications And Services
Smith+Nephew's H1 2026 results were a study in contrasts: trading profit surged 8.1% on the back of efficiency gains, yet revenue growth fell short of expectations, prompting a cut in the full-year revenue growth outlook from ~6% to ~4%. The profit beat and the decision to maintain profit and cash guidance underscore that the 12-Point Plan is delivering, but the top-line softness—particularly in US Orthopaedics and wound bioactives—casts doubt on the RISE strategy's growth trajectory. With the $500M buyback on track ($216M settled) and the dividend raised 4%, management is signaling confidence in cash generation. Against the backdrop of activist Cevian Capital building a stake above 14%, these results will be closely parsed for evidence of an operational turnaround or mounting pressure for strategic change.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.4% of the 1170 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNN was trading at $30.70 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $28.56 to $38.79. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.